Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

10.62 -0.36 (-3.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entrada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock ↗
 
Via Benzinga
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada (TRDA) Q2 Revenue Drops 98% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading ↗
Entrada Therapeutics (TRDA) missed Q2 2025 revenue and EPS estimates, posting $1.95M revenue vs. $9.84M expected and a $1.04 loss per share. Shares fell 2% pre-market amid investor concerns. Pipeline... 
Via Chartmill
Topics Earnings
News headline image
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports First Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy ↗
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces $100 Million Registered Direct Offering
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – 
From Entrada Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.